BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 27179263)

  • 1. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study.
    Depmann M; Eijkemans MJ; Broer SL; Scheffer GJ; van Rooij IA; Laven JS; Broekmans FJ
    Hum Reprod; 2016 Jul; 31(7):1579-87. PubMed ID: 27179263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added value of anti-Müllerian hormone in prediction of menopause: results from a large prospective cohort study.
    Dólleman M; Verschuren WM; Eijkemans MJ; Broekmans FJ; van der Schouw YT
    Hum Reprod; 2015 Aug; 30(8):1974-81. PubMed ID: 26082477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause.
    Dólleman M; Depmann M; Eijkemans MJ; Heimensem J; Broer SL; van der Stroom EM; Laven JS; Van Rooij IA; Scheffer GJ; Peeters PH; van der Schouw YT; Lambalk CB; Broekmans FJ
    Hum Reprod; 2014 Mar; 29(3):584-91. PubMed ID: 24435779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; McLernon DJ; Bhattacharya S; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2018 Sep; 33(9):1684-1695. PubMed ID: 30085143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced?
    van Tilborg TC; Derks-Smeets IA; Bos AM; Oosterwijk JC; van Golde RJ; de Die-Smulders CE; van der Kolk LE; van Zelst-Stams WA; Velthuizen ME; Hoek A; Eijkemans MJ; Laven JS; Ausems MG; Broekmans FJ
    Hum Reprod; 2016 Nov; 31(11):2651-2659. PubMed ID: 27907901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
    Lie Fong S; Laven JSE; Duhamel A; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of low ovarian reserve with cardiovascular disease risk: a cross-sectional population-based study.
    de Kat AC; Verschuren WM; Eijkemans MJ; van der Schouw YT; Broekmans FJ
    Hum Reprod; 2016 Aug; 31(8):1866-74. PubMed ID: 27496945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variation may modify ovarian reserve in female childhood cancer survivors.
    van Dorp W; van den Heuvel-Eibrink MM; Stolk L; Pieters R; Uitterlinden AG; Visser JA; Laven JS
    Hum Reprod; 2013 Apr; 28(4):1069-76. PubMed ID: 23360674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
    van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
    Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women.
    Verdiesen RMG; van der Schouw YT; van Gils CH; Verschuren WMM; Broekmans FJM; Borges MC; Gonçalves Soares AL; Lawlor DA; Eliassen AH; Kraft P; Sandler DP; Harlow SD; Smith JA; Santoro N; Schoemaker MJ; Swerdlow AJ; Murray A; Ruth KS; Onland-Moret NC
    Hum Reprod; 2022 May; 37(5):1069-1082. PubMed ID: 35274129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
    Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
    Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
    Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study.
    Koedooder R; Singer M; Schoenmakers S; Savelkoul PHM; Morré SA; de Jonge JD; Poort L; Cuypers WJSS; Beckers NGM; Broekmans FJM; Cohlen BJ; den Hartog JE; Fleischer K; Lambalk CB; Smeenk JMJS; Budding AE; Laven JSE
    Hum Reprod; 2019 Jun; 34(6):1042-1054. PubMed ID: 31119299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?
    Oudshoorn SC; van Tilborg TC; Hamdine O; Torrance HL; Eijkemans MJC; Lentjes EGWM; Lambalk CB; Broekmans FJM
    Hum Reprod; 2017 Aug; 32(8):1701-1709. PubMed ID: 28854580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESHRE guideline: ovarian stimulation for IVF/ICSI
    Ovarian Stimulation TEGGO; Bosch E; Broer S; Griesinger G; Grynberg M; Humaidan P; Kolibianakis E; Kunicki M; La Marca A; Lainas G; Le Clef N; Massin N; Mastenbroek S; Polyzos N; Sunkara SK; Timeva T; Töyli M; Urbancsek J; Vermeulen N; Broekmans F
    Hum Reprod Open; 2020; 2020(2):hoaa009. PubMed ID: 32395637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
    Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
    Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we predict age at natural menopause using ovarian reserve tests or mother's age at menopause? A systematic literature review.
    Depmann M; Broer SL; van der Schouw YT; Tehrani FR; Eijkemans MJ; Mol BW; Broekmans FJ
    Menopause; 2016 Feb; 23(2):224-32. PubMed ID: 26372034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.